Want to see GLUE full AI Analyst Report?
Top Page
Monte Rosa Therapeutics
(NASDAQ:GLUE)
Select Model
Select Model
Rating:50Neutral
Price Target:
$10.00
▼(-30.46% Downside)
Action:Reiterated
Date:10/01/26
GLUE scores in the middle primarily due to weak operating performance (falling revenue and large losses) and continued negative free cash flow, despite a low-leverage balance sheet. Technical indicators also remain bearish with the stock below major moving averages and negative MACD. Offsetting these risks, recent positive clinical/partnered milestones (including a $50M payment and strong Phase 1 data) provide meaningful pipeline momentum but are not sufficient to outweigh current financial and trend headwinds.
Positive Factors
Conservative leverage
Low debt relative to equity gives Monte Rosa financial flexibility while its clinical pipeline develops. This conservative leverage reduces balance-sheet pressure and may help the company fund research, partnerships, and clinical execution without relying solely on additional borrowing.
Negative Factors
Declining revenue
The sharp revenue decline indicates that reported commercial or partnership-related income is volatile and currently insufficient to support a stable growth trajectory. Persistently weaker revenue would make Monte Rosa more dependent on milestones, financing, or successful pipeline progression.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative leverage
Low debt relative to equity gives Monte Rosa financial flexibility while its clinical pipeline develops. This conservative leverage reduces balance-sheet pressure and may help the company fund research, partnerships, and clinical execution without relying solely on additional borrowing.
Read all positive factors
Monte Rosa Therapeutics (GLUE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$843.75M
Dividend YieldN/A
Average Volume (3M)1.29M
Price to Earnings (P/E)―
Beta (1Y)1.44
Revenue Growth-83.86%
EPS Growth-646.52%
CountryUS
Employees173
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.18
Shares Outstanding85,313,400
10 Day Avg. Volume1,660,561
30 Day Avg. Volume1,288,937
Financial Highlights & Ratios
PEG Ratio0.67
Price to Book (P/B)4.41
Price to Sales (P/S)8.31
P/FCF Ratio-37.37
Enterprise Value/Market Cap2.22
Enterprise Value/Revenue65.19
Enterprise Value/Gross Profit70.14
Enterprise Value/Ebitda-12.02
Forecast
1Y Price Target
$26.86Price Target Upside86.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.48
Revenue Forecast (FY)$67.80M
Monte Rosa Therapeutics Business Overview & Revenue Model
Company Description
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant ...
Monte Rosa Therapeutics Earnings Call Summary
Earnings Call Date:Mar 20, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:Nov 05, 2026
Earnings Call Sentiment Positive
The earnings call highlighted significant progress in clinical trials and strategic partnerships, particularly with the success of MRT-6160 and strategic agreement with Novartis. However, challenges such as lower than expected biomarker positivity in certain cancer cohorts and strategic shifts were noted. Overall, the positive developments and financial strength suggest a strong position for future growth.Positive Updates
MRT-6160 Phase 1 Study Success
The Phase 1 SAD/MAD study of MRT-6160 in healthy volunteers showed dose-dependent VAV1 degradation exceeding 90%, with significant inhibition of cytokine secretion up to 99%, and was well tolerated.
Negative Updates
Lower than Expected Biomarker Positivity
In the MRT-2359 Phase 1/2 study, there was a considerably lower than expected frequency of tumors with high L or N-MYC expression, affecting lung cancer and neuroendocrine tumor cohorts.
Read all updates
Q4-2024 Updates
Positive
Negative
MRT-6160 Phase 1 Study Success
The Phase 1 SAD/MAD study of MRT-6160 in healthy volunteers showed dose-dependent VAV1 degradation exceeding 90%, with significant inhibition of cytokine secretion up to 99%, and was well tolerated.
Read all positive updates
Company Guidance
During the Monte Rosa Therapeutics conference call held on March 20, 2025, several key metrics were discussed regarding the company's clinical and preclinical programs. The Phase 1 study of MRT-6160, a VAV1-directed molecular glue degrader, demonstrated significant pharmacodynamic effects with over 90% VAV1 degradation and up to 99% cytokine secretion inhibition, supporting progression to Phase 2 trials. The NEK7 program is on track for an IND submission in the first half of the year, with preclinical data showing potent NEK7 degradation and favorable safety profiles. In oncology, promising early data from the MRT-2359 program in castration-resistant prostate cancer showed a confirmed partial response and two stable diseases among three patients, prompting a focus on this indication. Monte Rosa plans to advance these programs with a strong cash runway extending into 2028.Monte Rosa Therapeutics Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
72
Positive
Cash Flow
41
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 28.73M | 123.67M | 75.62M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 26.70M | 115.32M | 67.50M | -6.22M | 0.00 | 0.00 |
| EBITDA | -155.85M | -31.37M | -62.01M | -128.79M | -100.99M | -71.83M |
| Net Income | -161.12M | -38.63M | -72.70M | -135.35M | -108.50M | -73.96M |
Balance Sheet | ||||||
| Total Assets | 696.08M | 448.66M | 438.73M | 303.75M | 342.39M | 366.33M |
| Cash, Cash Equivalents and Short-Term Investments | 621.10M | 377.10M | 372.15M | 232.41M | 262.83M | 346.07M |
| Total Debt | 37.99M | 39.19M | 42.72M | 46.04M | 47.00M | 0.00 |
| Total Liabilities | 211.03M | 215.60M | 215.80M | 124.50M | 70.98M | 18.81M |
| Stockholders Equity | 487.28M | 233.06M | 222.94M | 179.25M | 271.41M | 347.51M |
Cash Flow | ||||||
| Free Cash Flow | -32.08M | -27.50M | 38.01M | -62.84M | -105.38M | -69.09M |
| Operating Cash Flow | -24.07M | -22.80M | 42.00M | -43.80M | -92.47M | -59.36M |
| Investing Cash Flow | -316.79M | -101.83M | -44.45M | 88.80M | -219.22M | -9.65M |
| Financing Cash Flow | 361.52M | 30.35M | 98.89M | 27.49M | 20.47M | 377.56M |
Monte Rosa Therapeutics Technical Analysis
Negative
14.38
Price Trends
13.37
Negative
17.04
Negative
17.97
Negative
Market Momentum
-1.09
Negative
27.12
Positive
21.58
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GLUE, the sentiment is Negative. The current price of 14.38 is above the 20-day moving average (MA) of 11.30, above the 50-day MA of 13.37, and below the 200-day MA of 17.97, indicating a bearish trend. The MACD of -1.09 indicates Negative momentum. The RSI at 27.12 is Positive, neither overbought nor oversold. The STOCH value of 21.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GLUE.
Monte Rosa Therapeutics Risk Analysis
Monte Rosa Therapeutics disclosed 85 risk factors in its most recent earnings report. Monte Rosa Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Monte Rosa Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $447.24M | 35.89 | 1.91% | ― | -15.05% | ― | |
58 Neutral | $874.48M | -2.85 | -207.18% | ― | -7.27% | -48.89% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $843.75M | -4.51 | -43.31% | ― | -83.86% | -646.52% | |
47 Neutral | $342.01M | -2.61 | -45.45% | ― | 2.33% | 36.86% | |
43 Neutral | $875.73M | -1.59 | -102.97% | ― | -63.11% | 15.36% |
* Healthcare Sector Average
GLUE
Monte Rosa Therapeutics
9.84
-1.27
-11.43%
KURA
Kura Oncology
9.61
-0.68
-6.61%
ARVN
Arvinas Holding Company
6.82
-2.64
-27.91%
CCCC
C4 Therapeutics
2.61
0.39
17.57%
ALMS
Alumis Inc.
6.06
1.21
24.95%
ODTX
Odyssey Therapeutics, Inc.
16.60
0.18
1.10%
Monte Rosa Therapeutics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Monte Rosa Reports Positive Phase 1 Data for MRT-8102
Positive
Oct 1, 2026
On October 1, 2026, Monte Rosa Therapeutics reported positive topline data from its GFORCE-1 Phase 1 study of MRT-8102 in 108 obese subjects at elevated cardiovascular risk. The NEK7-directed molecular glue degrader achieved robust and sustained N...
Business Operations and StrategyPrivate Placements and FinancingProduct-Related Announcements
Monte Rosa earns milestone as MRT-6160 enters Phase 2
Positive
Sep 8, 2026
On September 8, 2026, Monte Rosa Therapeutics announced that collaborator Novartis has initiated a global Phase 2a/b clinical trial of VAV1-directed molecular glue degrader MRT-6160 (DDY391) in people with Sjögren’s disease, a progressi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.